Overview

Actively managed equity portfolio investing worldwide in biotech companies.

Efficient means of exploiting the potential of biotech companies operating in research, product development, production or distribution.

Specialised sector analysts seek out the most attractive stocks in the biotech sector worldwide.

Investment decisions are based on a disciplined investment philosophy and fundamental research.

The portfolio manager is not tied to the benchmark in terms of investment selection or weight.

Benefits

Easy access to the global biotech sector.

Offers investors broad diversification within the sector.

The fund taps into the knowledge of proven sector specialists.

麻豆社's proprietary fundamental valuation approach enables the most attractive biotechnology companies to be consistently identified.

Investors benefit from a global investment platform of 麻豆社 Asset Management.

Risks

麻豆社 Sector Funds invest in equities and may therefore be subject to high fluctuations in value. As these 麻豆社 Funds pursue an active management style, each Fund's performance can deviate substantially from that of its reference index. Focusing intentionally on individual sectors may entail additional risks. Sustainability risks are environmental, social or governance events or conditions that can have a material negative effect on the return, depending on the relevant sector, industry and company exposure. Sustainability risk: the risk arising from any environmental, social or governance events or conditions that, were they to occur, could cause a material negative impact on the value of the investment. All investments are subject to market fluctuations. Every Fund has specific risks, which can significantly increase under unusual market conditions. The fund can use derivatives, which may result in additional risks (particularly counterparty risk). This Fund may not be appropriate for investors who plan to withdraw their money before the recommended holding period disclosed in the PRIIPs KID, if available for this share class.

Features

Product category
麻豆社 Equity Funds
麻豆社 Sector Funds
Product domicile
Luxembourg
Portfolio management
麻豆社 Asset Management (Americas) LLC, New York
Fund management
麻豆社 Asset Management (Europe) S.A., Luxembourg
Custodian bank
麻豆社 Europe SE, Luxembourg Branch
Representative for products established under foreign law
麻豆社 Fund Management (Switzerland) AG
Day of inception
October 15, 1996
Currency of account
USD
Close of financial year
November 30
SFDR Classification
Art.8
Issue / redemption
daily
Distribution
Reinvestment
Maturity
Open end
Ongoing costs p.a.
2.12% p.a.
Management fee
1.63% p.a.
Total expense ratio (TER)
2.09% p.a.
Swing pricing
yes
Minimum investment
n.a.
Reference Index / Benchmark
MSCI US Investable Market Biotechnology 10/40 Index (r)
Securities no.
512723
ISIN
LU0069152568
Bloomberg Ticker
麻豆社EBIO LX
Telekurs Id
EQBIO

Performance and Prices

Percentage growth

as of May 27, 2026
Cumulative
USD(%) CHF(%) EUR(%)
YTD 4.02 3.32 5.08
1M
3M
6M
1Y
2Y 36.26 19.12 20.14
3Y
5Y 21.61 6.58 27.62
ø p.a.5Y 3.99 1.28 5.00

Current data

Net asset value 27.05.2026 USD 923.12
High - last 12 months 24.02.2026 USD 947.46
Low - last 12 months 28.05.2025 USD 605.65
Assets of the unit class in mn 27.05.2026 USD 403.53
Total product assets in mn 27.05.2026 USD 462.58
Statistical data
Date
2 years
5 years
Total risk reference index / benchmark 30.04.2026 15.52% 17.01%
Sharpe Ratio 30.04.2026 0.76 -0.03
Risk Free Rate 30.04.2026 4.48% 3.57%

Structures

By the 10 largest equity positions (in %, as of April 30, 2026)

 
 
Vertex Pharmaceuticals Inc 9.14
Insmed Inc 5.28
Ionis Pharmaceuticals Inc 4.41
Arrowhead Pharmaceuticals Inc 4.29
Roivant Sciences Ltd 3.93
AbbVie Inc 3.68
Amgen Inc 3.56
Gilead Sciences Inc 3.54
Royalty Pharma PLC 3.47
BioNTech SE 3.41

Fees

Ongoing costs p.a.
2.12%
Flat fee
2.04%
Management fee p.a.
1.63%
Max. redemption commission
0.00%
Max. issuing commission
5.00%
Swiss federal stamp duty
0.15%
Distribution fee
(see info)

Distributions

No distributions. Continuous reinvestment of income.

Sales Authorisations

Market
Sales authorisations status
Austria
Registered
Chile
Institutional Only*
Cyprus
Registered
Denmark
Registered
Finland
Registered
France
Registered
Germany
Registered
Greece
Registered
Italy
Registered
Liechtenstein
Registered
Luxembourg
Registered
Malta
Registered
Netherlands
Registered
Norway
Registered
Portugal
Registered
Republic of Korea
Registered
Singapore
Institutional Only*
Spain
Registered
Sweden
Registered
Switzerland
Registered
Taiwan
Registered
United Kingdom
Registered

Literature

Brochures
Document type
Document Language
Fact Sheet
Manager Commentary
Swiss Climate Scores Report
ASIP ESG Report
Fact Sheet - 麻豆社 Equity Funds
Fact Sheet - 麻豆社 Sector Funds
Agreement / Prospectus
Document type
Document Language
Prospectus
Key Information Document
Past performance
Previous performance scenario
Statutes / Management regulations
ESG Disclosure
SFDR Pre-Contractual Annex
Annual and semi-annual report (accounting on November 30)
Document type
Document Language
Annual report
SFDR Periodic Report Annex
Semi-annual report
General information
Document type
Document Language
Tax list
Please wait for the requested content to load. If there is no response after several minutes, please reload the page or try again later.